You are here: Home: Audio Program Guide: CCU Surgeons 2 | 2007 Audio: CCU Surgeons 2 | 2007
Go to interview with Bruce Minsky, MD Go to interview with Axel Grothey, MD Go to interview with Anton Bilchik, MD, PhD Go to interview with Alan P Venook, MD
To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.

 

Bruce Minsky, MD Associate Dean and Professor of Radiation and Cellular Oncology Chief Quality Officer University of Chicago Medical Center
	Click here to download the entire interview
Track 1	Staging modalities for rectal cancer
Track 2	Treatment algorithms for T1-T2, node-negative rectal cancer
Track 3	Neoadjuvant chemoradiation therapy followed by surgery and postoperative chemotherapy for rectal cancer
Track 4	Capecitabine versus 5-FU as treatment for colon and rectal cancer
Track 5	Morbidity of oxaliplatin in combination with radiation therapy
Track 6	Clinical trials evaluating chemotherapy combined with biologic agents
Track 7	Potential impact of bevacizumab on the efficacy of radiation therapy
Track 8	Oxaliplatin-based therapy in the adjuvant and neoadjuvant settings
Track 9	Adequacy of lymph node sampling in rectal cancer
Track 10	Relationship between quality of surgery and outcome
Track 11	Management of local recurrences after chemoradiation therapy and surgery
Track 12	Long-term complications of radiation therapy for rectal cancer
Track 13	FOLFOX and bevacizumab for synchronous primary and metastatic rectal cancer
Track 14	Response rates in primary rectal tumors treated with CAPOX
Track 15	Correlation between diet, exercise and recurrence in patients with primary colorectal cancer
Track 16	Evolution of the treatment for rectal cancer

Axel Grothey, MD Professor of Oncology Department of Medical Oncology Mayo Clinic Rochester, Minnesota
	Click here to download the entire interview
Track 1	Adequacy of lymph node sampling in staging colorectal cancer and potential impact on treatment decisions
Track 2	Disparity in lymph node sampling between NCCN centers and the SEER database
Track 3	Oxaliplatin-based chemotherapy in the treatment of Stage II versus Stage III colorectal cancer
Track 4	Adjuvant capecitabine for patients with lower-risk, Stage II disease
Track 5	Cumulative peripheral neurotoxicity secondary to oxaliplatin
Track 6	Basing treatment on comorbidities rather than age in elderly patients
Track 7	Clinical trials evaluating the role of bevacizumab in the adjuvant setting
Track 8	Incidence and etiology of bowel perforation secondary to bevacizumab
Track 9	Wound healing and bevacizumab
Track 10	Resection of limited hepatic and/or pulmonary metastases with the intent to cure
Track 11	Timing of bevacizumab in the pre- and postoperative settings
Track 12	Neoadjuvant versus adjuvant radiochemotherapy for the treatment of rectal cancer
Track 13	NSABP-R-04: Preoperative capecitabine or 5-FU, with or without oxaliplatin, with radiation therapy for rectal cancer

Anton Bilchik, MD, PhD Director of the Gastrointestinal Program John Wayne Cancer Institute Santa Monica, California
	Click here to download the entire interview
Track 1	Adequate lymph node resection for staging
Track 2	Importance of adequate mesenteric resection to improve lymph node sampling
Track 3	Use of adjuvant chemotherapy for patients with inadequate lymph node staging
Track 4	Laparoscopic versus open colectomy
Track 5	Timing of bevacizumab administration relative to surgery
Track 6	Conversion of unresectable hepatic metastases to resectable disease with curative intent
Track 7	Use of intra-arterial hepatic infusion of chemotherapy
Track 8	Diagnostic tools for staging rectal cancer
Track 9	Treatment of T1-T2, node-negative rectal cancer
Track 10	Capecitabine and/or oxaliplatin in the treatment of rectal cancer in the adjuvant setting
Track 11	Total mesorectal excision in rectal cancer

Alan P Venook, MD Professor of Clinical Medicine University of California, San Francisco San Francisco, California
	Click here to download the entire interview
Track 1	Impact of the MOSAIC trial data on the use of FOLFOX for early colon cancer
Track 2	Adjuvant therapy for patients with Stage II colon cancer and insufficient nodal sampling
Track 3	Neurotoxicity associated with the use of oxaliplatin
Track 4	Adjuvant capecitabine versus intravenous 5-FU in clinical practice
Track 5	Systemic therapy versus surgery as front-line treatment for patients presenting with synchronous colon cancer and metastatic disease
Track 6	Efficacy and safety of adding bevacizumab to front-line FOLFOX in treating metastatic disease
Track 7	Mechanism of action of bevacizumab
Track 8	Clinical trial of adjuvant FOLFOX with or without bevacizumab
Track 9	Rationale for systemic therapy before surgery for resectable hepatic metastases
Track 10	Use of systemic therapy to convert unresectable metastases to resectable disease
Track 11	Use of intrahepatic chemotherapy in clinical practice
Track 12	Neoadjuvant chemoradiation therapy and postsurgical adjuvant therapy for rectal cancer
Track 13	Role of endorectal ultrasound in staging rectal cancer